Elagolix Suppresses Ovulation in a Dose-Dependent Manner: Results From a 3-Month, Randomized Study in Ovulatory Women

David F Archer, Juki Ng, Kristof Chwalisż, Kristof Chwalisz, Yi‐Lin Chiu, Yi-Lin Chiu, Eve C Feinberg, Charles E Miller, Robert A Feldman, Robert Feldman, Cheri E Klein
The Journal of clinical endocrinology and metabolism · 2019 · vol. 105(3) , pp. 821–832 · doi:10.1210/clinem/dgz086 · PMID:31650182 · W2981884531
article OA: bronze CC0 ⤵ 9 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

Elagolix suppressed ovulation and key sex hormones in a dose-dependent manner, with the lowest ovulation rates observed at the highest elagolix dose combined with hormone add-back therapy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

CONTEXT: Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist recently approved for the treatment of endometriosis-associated pain and being developed for heavy menstrual bleeding associated with uterine fibroids. OBJECTIVE: The objective was to evaluate the effects of elagolix on ovulation and ovarian sex hormones. DESIGN AND SETTING: This was a randomized, open-label, multicenter study. PARTICIPANTS: Participants were healthy ovulatory women aged 18 to 40 years. INTERVENTIONS: Elagolix was administered orally for 3 continuous 28-day dosing intervals at 100 to 200 mg once daily (QD), 100 to 300 mg twice daily (BID), and 300 mg BID plus estradiol/norethindrone acetate (E2/NETA) 1/0.5 mg QD. MAIN OUTCOME MEASURES: The main outcomes measures were ovulation rates measured by transvaginal ultrasound, progesterone concentrations, and hormone suppression. RESULTS: Elagolix suppressed ovulation in a dose-dependent manner. The percentage of women who ovulated was highest at 100 mg QD (78%), intermediate at 150 and 200 mg QD and 100 mg BID (47%-57%), and lowest at 200 and 300 mg BID (32% and 27%, respectively). Addition of E2/NETA to elagolix 300 mg BID further suppressed the ovulation rate to 10%. Elagolix also suppressed luteinizing hormone and follicle stimulating hormone in a dose-dependent manner, leading to dose-dependent suppression of estradiol and progesterone. Elagolix had no effect on serum biomarker of ovarian reserve, and reduced endometrial thickness compared to the screening cycle. CONCLUSION: Women being treated with elagolix may ovulate and should use effective methods of contraception. The rate of ovulation was lowest with elagolix 300 mg BID plus E2/NETA 1/0.5 mg QD.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometrium Gonadotropin-Releasing Hormone Hydrocarbons, Fluorinated Menorrhagia Ovulation Pyrimidines Adolescent Adult Dose-Response Relationship, Drug Endometrium Female Follow-Up Studies Gonadotropin-Releasing Hormone Hormone Antagonists Hormone Antagonists Hormone Antagonists Humans Hydrocarbons, Fluorinated Hydrocarbons, Fluorinated Menorrhagia

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (24)

Cited by (9)

Source provenance

europepmc
last seen: 2026-07-03T06:58:25.718087+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:22:29.487098+00:00
License: CC0 · commercial use OK